Dambkowski Carl sold $433K of APGE
Dambkowski Carl (Chief Medical Officer) sold 5,500 shares of Apogee Therapeutics, Inc. (APGE) at $78.71 ($0.43M total) on 2026-06-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Insider selling can influence sentiment, but 10b5-1 plans are designed to reduce timing-based inference.
Market read
A routine insider sale disclosure for APGE; likely sentiment-only impact with low trading urgency.
What to watch
The filing does not specify reasons for the sale or any concurrent buying; without additional context, interpretive value is limited.
Background
The article is an SEC Form 4 insider transaction disclosure for Apogee Therapeutics, Inc.
Ticker impact
Apogee Therapeutics CMO Dambkowski Carl sold $432,905 of APGE stock in an open-market transaction dated June 3 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment/flow effects.
The filing is a routine Form 4 open-market sale with an indicated pre-arranged 10b5-1 plan, which typically reduces interpretive signal.
Market effects
Minimal; single-company insider sale without new clinical/regulatory or deal information.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.
Key entities
- issuerApogee Therapeutics, Inc.
Subject of the Form 4 insider sale by its Chief Medical Officer.
- insiderDambkowski Carl
Chief Medical Officer who executed an open-market sale under a 10b5-1 plan.
